Phenotypic heterogeneity of myelodysplastic cells and influence of epigenetic therapies (WP1)
Rationale and objectives
The role of phenotypic, notably transcriptomic, heterogeneity in disease progression is not known. We will test how therapies with epidrugs (HMAs and IDH inhibitors) channel this heterogeneity.
Our objectives are:
• To prospectively compare the evolution of heterogeneity (scRNA+DNA-seq) in MDS/sAML patients treated with HMAs.
• To integrate in collaboration with the Santini group transcriptomic evolution with DNA methylation.
• To retrospectively analyze the genetic and transcriptomic evolution of IDH-mutated MDS patients treated in clinical trials.
GenomeScan B.V. (The Netherlands, 2 months), University of Bergen (Norway, 2 months).
Université de Paris